Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil + silodosin + paroxetine for premature ejaculation
PACTR202211709374727Phase 2Not yet recruiting
- Sponsor
- Zyvran Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tadalafil, silodosin and paroxetine in premature ejaculation (PE) (2 arms), sponsored by Zyvran Pharmaceuticals. Primary endpoint: Intravaginal ejaculatory latency time. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
tadalafilsilodosinparoxetine
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on PACTR202211709374727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202211709374727.